Caribou Biosciences (NASDAQ:CRBU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01, Zacks reports. The company had revenue of $2.08 million during the quarter, compared to analysts' expectations of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

Caribou Biosciences Stock Performance

CRBU traded up $0.03 during trading on Friday, reaching $1.02. The company's stock had a trading volume of 398,481 shares, compared to its average volume of 1,276,161. Caribou Biosciences has a 52-week low of $0.98 and a 52-week high of $5.77. The company's fifty day moving average price is $1.38 and its 200-day moving average price is $1.79. The company has a market capitalization of $91.91 million, a price-to-earnings ratio of -0.62 and a beta of 2.34.

Analysts Set New Price Targets

CRBU has been the topic of several recent research reports. Citigroup cut their price target on Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, November 26th. Bank of America dropped their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has a consensus rating of "Buy" and an average target price of $10.33.

Remove Ads

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.